Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/30263
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mulley W. | en |
dc.contributor.author | Kanellis J. | en |
dc.contributor.author | Huang L. | en |
dc.date.accessioned | 2021-05-14T10:13:36Z | en |
dc.date.available | 2021-05-14T10:13:36Z | en |
dc.date.copyright | 2011 | en |
dc.date.created | 20110221 | en |
dc.date.issued | 2012-10-05 | en |
dc.identifier.citation | Nephrology. 16 (2) (pp 239-242), 2011. Date of Publication: February 2011. | en |
dc.identifier.issn | 1320-5358 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/30263 | en |
dc.description.abstract | Intravenous immunoglobulin (IVIg) therapy for antibody-mediated rejection (AMR) is increasing and is associated with a small but significant incidence of thrombosis. We determined thrombosis rates in patients treated with high-dose IVIg for AMR before and after alteration of an infusion protocol. The newer protocol introduced routine administration of aspirin 300 mg, enoxaparin 1 mg/kg, intravenous hydration and a maximum infusion rate of 100 mg/kg per hour (previously 200 mg/kg per hour). Nine thromboses in 275 infusions occurred before the protocol alteration (event rate 3.3%). Two were arterial thromboses including an acute myocardial infarct and a renal transplant artery thrombosis, which resulted in infarction of 2/3 of the graft. Seven venous thromboses occurred, six in arteriovenous fistulae and one case with bilateral above knee deep venous thromboses. Significant associations with thromboses were seen with higher IVIg dose and male sex. In the 6 months since the introduction of the new infusion protocol, 74 infusions have been administered with no thrombotic events. There have been no significant bleeding or fluid overload side-effects. Infusion times, however, have been doubled. A slower rate of infusion combined with antiplatelet and anticoagulation has thus far eliminated the small but significant IVIg-related thrombosis rate previously observed in our patients treated for AMR without resulting in significant side-effects. Further study is now required to define which elements of this protocol are essential. © 2011 Asian Pacific Society of Nephrology. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing (550 Swanston Street, Carlton South VIC 3053, Australia) | en |
dc.title | Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. [Nephrology] | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/j.1440-1797.2010.01399.x | en |
dc.publisher.place | Australia | en |
dc.identifier.pubmedid | 21272138 [http://www.ncbi.nlm.nih.gov/pubmed/?term=21272138] | en |
dc.identifier.source | 361199357 | en |
dc.identifier.institution | (Huang, Kanellis, Mulley) Department of Nephrology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia (Kanellis, Mulley) Department of Medicine, Monash University, Clayton, VIC, Australia | en |
dc.description.address | L. Huang, Department of Nephrology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia. E-mail: louis.huang@southernhealth.org.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2012 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | antibody-mediated rejection intravenous immunoglobulin thrombosis | en |
dc.identifier.authoremail | Huang L.; louis.huang@southernhealth.org.au | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Nephrology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.